Pelthos Therapeutics Inc. (PTHS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pelthos Therapeutics Inc. (PTHS) has a cash flow conversion efficiency ratio of -0.161x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.25 Million) by net assets ($38.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Pelthos Therapeutics Inc. stock price for real-time trading data and today's change.
Pelthos Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Pelthos Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Pelthos Therapeutics Inc. stock valuation for the company's overall valuation and market capitalisation.
Pelthos Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pelthos Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see PTHS total asset value for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Park Dental Partners, Inc. Common Stock
NASDAQ:PARK
|
0.039x |
|
Chuwa Wool Industry Co Taiwan Ltd
TW:1439
|
0.032x |
|
MFS High Yield Municipal Closed Fund
NYSE:CMU
|
0.024x |
|
KGL Resources Limited
F:KN6
|
-0.003x |
|
Kothari Petrochemicals Limited
NSE:KOTHARIPET
|
0.130x |
|
Visaka Industries Limited
NSE:VISAKAIND
|
0.060x |
|
Malindo Feedmill Tbk
JK:MAIN
|
-0.003x |
|
OM INFRA LIMITED
NSE:OMINFRAL
|
-0.050x |
Annual Cash Flow Conversion Efficiency for Pelthos Therapeutics Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Pelthos Therapeutics Inc. from 2021 to 2025. Review PTHS financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $38.88 Million | $-22.59 Million | -0.581x | -127.22% |
| 2024-12-31 | $-2.71 Million | $-5.79 Million | 2.134x | +1302.03% |
| 2023-12-31 | $-6.44 Million | $-981.03K | 0.152x | -64.00% |
| 2022-12-31 | $-3.71 Million | $-1.57 Million | 0.423x | -2.32% |
| 2021-12-31 | $-3.68 Million | $-1.59 Million | 0.433x | -- |
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus… Read more